source
- Viking touts once-a-month weight loss maintenance dataViking Therapeutics says patients who switched to a once-a-month dosing regimen of its obesity drug did not regain much weight after 12 weeks, bolstering the potential of a less frequent schedule.…
- Vertex opens up larger kidney disease opportunity with mid-stage readoutWhile Vertex is laser-focused on an upcoming FDA decision for povetacicept in immunoglobulin A nephropathy, the APOL1 inhibitor inaxaplin has demonstrated potential “best-in-class” data in a differ…BioSpace · 29d ago↗ source
- Telix to acquire ITM Isotope Technologies for $1.65 billion, adding late-stage radiopharma asset ITM-11